STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNYA
  4. [Form 4] Tenaya Therapeutics, Inc. Insider Trading Activity

Tenaya Therapeutics (TNYA) CEO receives 158,600 RSUs and 952,250-share stock option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. reported an equity award grant to its Chief Executive Officer, Ali Faraz. On February 3, 2026, he received 158,600 shares of common stock in the form of restricted stock units at a price of $0 per share, which will vest in installments beginning August 15, 2026 and then every six months until fully vested. He also received a stock option for 952,250 shares of common stock at an exercise price of $0.915 per share, vesting monthly over four years starting one month after the grant date. Following these grants, he beneficially owned 458,266 shares of common stock, including 369,875 shares underlying restricted stock units, and 952,250 stock options, all held directly.

Positive

  • None.

Negative

  • None.
Insider Ali Faraz
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 952,250 $0.00 --
Grant/Award Common Stock 158,600 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 952,250 shares (Direct); Common Stock — 458,266 shares (Direct)
Footnotes (1)
  1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. Includes 369,875 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ali Faraz
(Last) (First) (Middle)
C/O TENAYA THERAPEUTICS, INC.
171 OYSTER POINT BLVD., 5TH FLOOR
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 02/03/2026(2) A 158,600 A $0 458,266(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy) $0.915 02/03/2026 A 952,250 03/03/2026(4) 02/02/2036 Common Stock 952,250 $0 952,250 D
Explanation of Responses:
1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.
2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.
3. Includes 369,875 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
4. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact 02/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Tenaya Therapeutics (TNYA) report for its CEO?

Tenaya Therapeutics reported new equity awards to CEO Ali Faraz. He received 158,600 restricted stock units and a stock option for 952,250 shares, both granted on February 3, 2026 under the 2021 Equity Incentive Plan, with multi-year vesting schedules.

How many Tenaya Therapeutics (TNYA) shares did the CEO acquire in this Form 4?

The CEO acquired 158,600 shares of Tenaya Therapeutics common stock in the form of restricted stock units. These units convert into shares as they vest over time, starting August 15, 2026, with additional vesting every six months until the award is fully vested.

What stock option did the Tenaya Therapeutics (TNYA) CEO receive?

Ali Faraz received a stock option covering 952,250 shares of Tenaya Therapeutics common stock at an exercise price of $0.915 per share. The option vests in 1/48th monthly installments, starting one month after the February 3, 2026 grant date, until fully vested by February 2030.

What is the vesting schedule for the new restricted stock units at Tenaya Therapeutics (TNYA)?

The restricted stock units granted on February 3, 2026 vest as to 1/8 of the total shares on August 15, 2026. Another 1/8 vests every six months thereafter, so the CEO’s 158,600 units fully vest after four years of semiannual vesting.

How many Tenaya Therapeutics (TNYA) shares does the CEO beneficially own after these grants?

After the reported transactions, the CEO beneficially owned 458,266 shares of Tenaya Therapeutics common stock directly. This figure includes 369,875 shares that will be issued upon vesting of restricted stock units, in addition to his newly granted 158,600-unit award.

Are the Tenaya Therapeutics (TNYA) CEO’s new equity awards part of a company plan?

Yes. Both the 158,600 restricted stock units and the 952,250-share stock option were granted under Tenaya Therapeutics’ 2021 Equity Incentive Plan. This plan provides for equity-based compensation to executives and other eligible participants, subject to defined vesting conditions.